NCNA NuCana plc Sponsored ADR

NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar

NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar
EN
13/10/2020

Underlying

NCNANuCana plc Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NuCana plc Sponsored ADR

 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in...

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China EDINBURGH, United Kingdom, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the China National Intellectual Property Administration (“CNIPA”) has granted an important patent covering the composition of matter for NUC-7738.   This patent (ZL 202010794701.2) is expected to serve as a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition of matter patent covers the chemical structure of ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 ...

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738 BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) presented data at the European Society for Medical Oncology Congress 2025 (“ESMO”) on a new model system investigating the synergistic effects of N...

October 18, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Announces Encouraging Data for NUC-3373 in Combination with Ant...

NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows Patient with Melanoma Remains Progression-Free at 23 Months with a Durable Partial Response Preclinical Data Corroborate Immunogenic Effects of NUC-3373 Observed in Patients EDINBURGH, United Kingdom, Oct. 14, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced the publication of new data on NUC-3373. The update includes resul...

October 14, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Compliant with All Nasdaq Continued Listing Criteria

NuCana Compliant with All Nasdaq Continued Listing Criteria Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced that it has received formal notification from The Nasdaq Stock Market on September 4, 2025 confirming that the Company is in compliance with all applicable Nasdaq continued listing criteria, including the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As such, the previously disclosed Nasdaq listing matter has been closed. “As a result of the ...

September 5, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at t...

NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025 EDINBURGH, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced a presentation at the upcoming annual European Society for Medical Oncology (“ESMO”) congress being held October 17-21, 2025 in Berlin, Germany (the “ESMO Congress 2025”). The details of NuCana’s presentation at the meeting are as follows: Abstract Title: Patient Derived Organoids Reveal Synergy Between NUC-7738 and PD-1 Inhibition in Renal Cell Cancer Poster Number: 1530P...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch